◆英語タイトル:Autolus Therapeutics Plc (AUTL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8134
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Autolus Therapeutics Plc (Autolus), formerly Autolus Therapeutics Limited is a clinical-stage biopharmaceutical company which offers programmed T cell immunotherapies for the treatment of hematological cancers and solid tumors. The company utilizes its T-cell programming and manufacturing technologies to develop chimeric antigen receptors (CARs) or T-cell receptors (TCRs) to identify cancer cells, break down their defence mechanisms and kill these cells. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programmes. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, the UK.
Autolus Therapeutics Plc (AUTL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Autolus Raises USD80 Million in Series C Financing 10
Autolus Raises USD56 Million in Series B Financing 12
Autolus Raises USD45.4 Million in Series A Financing 13
Licensing Agreements 14
Autolus Enters into Licensing Agreement with UCL Business 14
Autolus Amends Licensing Agreement with UCL Business 15
Equity Offering 16
Autolus Raises USD172.5 Million in IPO of Shares 16
Autolus Spin Out from University College London 18
Autolus Therapeutics Plc – Key Competitors 19
Autolus Therapeutics Plc – Key Employees 20
Autolus Therapeutics Plc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Corporate Communications 22
Oct 17, 2018: Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality 22
Jun 08, 2018: Autolus announces appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer 23
Jun 08, 2018: Autolus Names Linda Bain to its Board of Directors 24
Mar 12, 2018: Autolus Appoints Cynthia M. Butitta As Board Director 25
Jul 18, 2017: Autolus Announces Senior Leadership Appointments 26
Government and Public Interest 27
Mar 15, 2018: Autolus to support UK network of Advanced Therapies Treatment Centres 27
Clinical Trials 28
Apr 17, 2018: Autolus announces presentation of preliminary data showing early signs of clinical activity for a GD2-targeting CAR T cell therapy in a solid tumour setting at the AACR Annual Meeting 28
Mar 21, 2018: Autolus Announces Oral Presentation at the AACR Annual Meeting of a Phase I study of a GD2 CAR-T Cell Therapy in Patients with Neuroblastoma 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Autolus Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Autolus Raises USD80 Million in Series C Financing 10
Autolus Raises USD56 Million in Series B Financing 12
Autolus Raises USD45.4 Million in Series A Financing 13
Autolus Enters into Licensing Agreement with UCL Business 14
Autolus Amends Licensing Agreement with UCL Business 15
Autolus Raises USD172.5 Million in IPO of Shares 16
Autolus Spin Out from University College London 18
Autolus Therapeutics Plc, Key Competitors 19
Autolus Therapeutics Plc, Key Employees 20
List of Figures
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Autolus Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8